Match!
Arun J. Sanyal
Virginia Commonwealth University
Nonalcoholic fatty liver diseaseCirrhosisDiabetes mellitusMedicineGastroenterology
834Publications
104H-index
45.3kCitations
What is this?
Publications 884
Newest
#1Emily C. Bendel (Mayo Clinic)H-Index: 4
#2Kenneth W. Sniderman (UHN: University Health Network)H-Index: 13
Last. Ziv J Haskal (UVA: University of Virginia)H-Index: 9
view all 10 authors...
Abstract Purpose To evaluate feasibility, procedural outcomes, and safety aspects of implantation of the alfapump system for management of refractory ascites by interventional radiology (IR) methods. Materials and Methods The multicenter open-label prospective MOSAIC study included 29 patients (mean age 60.0 y ± 9.9; range, 32–72 y, 17 [56.7%] male) with cirrhotic refractory ascites who received an alfapump system implanted by IR. The fully subcutaneous alfapump system consists of a pump and 2 s...
Source
#1Margery A. ConnellyH-Index: 30
#2Jonathan Velez Rivera (Duke University)
Last. Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 104
view all 5 authors...
BACKGROUND Patients with non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, are at higher risk of cardiovascular disease (CVD) and associated mortality. Therefore, it is important to understand how new therapies for non-alcoholic steatohepatitis (NASH) may impact CVD risk factors in these patients. AIMS To summarise the effects of drug therapies on lipid and lipoprotein levels in patients with NASH and provide insight into the potential mechanisms for the ...
Source
#1Davide Povero (UCSD: University of California, San Diego)H-Index: 19
#2Hirokazu Yamashita (UCSD: University of California, San Diego)
Last. Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 104
view all 12 authors...
Source
#1Beth A. Davison (Durham University)H-Index: 36
#2Stephen A. Harrison (University of Oxford)H-Index: 36
Last. Howard C. DittrichH-Index: 26
view all 10 authors...
Abstract Background & aims Liver biopsies are a critical component of pivotal studies in nonalcoholic steatohepatitis (NASH) constituting main inclusion criteria, risk stratification factors and endpoints. We evaluated the reliability of NASH Clinical Research Network scoring of liver biopsies in a NASH clinical trial. Methods Digitized slides from 678 biopsies for 339 patients with paired biopsies randomized into the EMMINENCE study examining a novel insulin sensitizer (MSDC-0602K) in NASH were...
Source
#1Zobair M. Younossi (Inova Health System)H-Index: 73
#2Mary E. Rinella (NU: Northwestern University)H-Index: 30
Last. Rohit Loomba (UCSD: University of California, San Diego)H-Index: 64
view all 8 authors...
The term nonalcoholic fatty liver disease (NAFLD) was initially introduced by Schaffner in 1986. NAFLD is a clinical entity characterized by the presence of hepatic steatosis affecting at least 5% of hepatocytes in individuals who consume little or no alcohol and who do not have a secondary cause of hepatic steatosis such as viral hepatitis, medications (such as tamoxifen, amiodarone and methotrexate, among others), or lipodystrophy.
Source
#1Divya P. Kumar (JSS Medical College)H-Index: 1
#2Rebecca CaffreyH-Index: 1
Last. Suresh GiriH-Index: 8
view all 12 authors...
Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ agonist would improve NASH in the diet-induced animal model of NAFLD. Mice received chow diet and normal water (CDNW) or high fat western diet and ad lib sugar water (WDSW). After 12 weeks, WDSW fed mice were randomized to receive (1) WDSW alone, (2) WDSW + vehicle, (3) WDSW + pioglitazone or (4) WDSW + saroglitazar...
1 CitationsSource
#1Kenneth CusiH-Index: 52
#2Michael RodenH-Index: 5
Last. Miriam B. VosH-Index: 27
view all 17 authors...
Source
#1Aline de Conti (NCTR: National Center for Toxicological Research)H-Index: 16
#2Volodymyr Tryndyak (NCTR: National Center for Toxicological Research)H-Index: 32
Last. Mark I. Avigan (CDER: Center for Drug Evaluation and Research)H-Index: 13
view all 16 authors...
Interindividual variability and sexual dimorphisms in the development of nonalcoholic fatty liver disease (NAFLD) are still poorly understood. In the present study, male and female strains of Collaborative Cross (CC) mice were fed a high-fat and high-sucrose (HF/HS) diet or a control diet for 12 weeks to investigate interindividual- and sex-specific variations in the development of NAFLD. The severity of liver steatosis varied between sexes and individual strains and was accompanied by an elevat...
Source
#1Lorraine McSweeney (Newcastle University)H-Index: 3
#2Matthew Breckons (Newcastle University)H-Index: 10
Last. Fiona Beyer (Newcastle University)H-Index: 25
view all 12 authors...
Abstract Background The inflammatory form of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), is known to have a negative impact on patients' health-related quality of life (HRQoL), even before progression to cirrhosis has occurred. Previous work has been undertaken to develop a Patient Reported Outcome Measure (PROM) to assess the impact and burden of disease in the non-cirrhotic NASH patient. The burden of cirrhotic NASH from the patient perspective remains poor...
1 CitationsSource
#1Sophie C. Cazanave (VCU: Virginia Commonwealth University)H-Index: 24
#2Alexei A. Podtelezhnikov (MSD: Merck & Co.)H-Index: 10
Last. Abdul M. Oseini (VCU: Virginia Commonwealth University)H-Index: 5
view all 17 authors...
Source
12345678910